The Lancet Haematology in conversation with Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

https://thelancethaematology.buzzsprout.com/1564352/15618307-matteo-della-porta-on-the-phase-3-commands-trial-examining-luspatercept-versus-epoetin-alfa-in-patients-with-lower-risk-myleodysplastic-syndrome?utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz-8eBV1wsn46XSujmWOxaoU2A5f04Cqrsb-aWbMrnS6f0-VtLnRrQKW4LlyGnmzwKqN8K-R-gBn53-cZgktw-JBKFtdEBw&_hsmi=322652483&utm_content=322446729&utm_source=hs_email